A citation-based method for searching scientific literature

Nicoletta Machin, Margaret V Ragni. J Blood Med 2018
Times Cited: 45







List of co-cited articles
426 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
Manisha Balwani, Eliane Sardh, Paolo Ventura, Paula Aguilera Peiró, David C Rees, Ulrich Stölzel, D Montgomery Bissell, Herbert L Bonkovsky, Jerzy Windyga, Karl E Anderson,[...]. N Engl J Med 2020
154
6

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Kausik K Ray, R Scott Wright, David Kallend, Wolfgang Koenig, Lawrence A Leiter, Frederick J Raal, Jenna A Bisch, Tara Richardson, Mark Jaros, Peter L J Wijngaard,[...]. N Engl J Med 2020
277
6

Therapeutic siRNA: state of the art.
Bo Hu, Liping Zhong, Yuhua Weng, Ling Peng, Yuanyu Huang, Yongxiang Zhao, Xing-Jie Liang. Signal Transduct Target Ther 2020
209
6

Overview of the coagulation system.
Sanjeev Palta, Richa Saroa, Anshu Palta. Indian J Anaesth 2014
274
6

Novel therapies and current clinical progress in hemophilia A.
Pauline Balkaransingh, Guy Young. Ther Adv Hematol 2018
24
12


Gene Therapy for Coagulation Disorders.
Laura L Swystun, David Lillicrap. Circ Res 2016
10
30

Gene therapy for hemophilia: what does the future hold?
Bhavya S Doshi, Valder R Arruda. Ther Adv Hematol 2018
54
6

Synthesis of 5'-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies.
Isaiah Cedillo, Dana Chreng, Elyse Engle, Lijian Chen, Andrew K McPherson, Andrew A Rodriguez. Molecules 2017
7
28

Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates.
Trinna L Cuellar, Dwight Barnes, Christopher Nelson, Joshua Tanguay, Shang-Fan Yu, Xiaohui Wen, Suzie J Scales, Julie Gesch, David Davis, Anja van Brabant Smith,[...]. Nucleic Acids Res 2015
105
4

Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
James O McNamara, Eran R Andrechek, Yong Wang, Kristi D Viles, Rachel E Rempel, Eli Gilboa, Bruce A Sullenger, Paloma H Giangrande. Nat Biotechnol 2006
713
4

Bevasiranib for the treatment of wet, age-related macular degeneration.
Adinoyi O Garba, Shaker A Mousa. Ophthalmol Eye Dis 2010
68
4



Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Shannon Hall, Jennifer Burkey, Colby S Shemesh, Thazha P Prakash, Punit P Seth,[...]. Mol Ther Nucleic Acids 2016
56
4

Enhancing Endosomal Escape for Intracellular Delivery of Macromolecular Biologic Therapeutics.
Peter Lönn, Apollo D Kacsinta, Xian-Shu Cui, Alexander S Hamil, Manuel Kaulich, Khirud Gogoi, Steven F Dowdy. Sci Rep 2016
148
4



Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.
Sterghios Athanasios Moschos, Simon Wyn Jones, Mark Michael Perry, Andrew Evan Williams, Jonas Sten Erjefalt, John James Turner, Peter John Barnes, Brian Stephen Sproat, Michael John Gait, Mark Andrew Lindsay. Bioconjug Chem 2007
242
4

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.
Sven Kruspe, Paloma H Giangrande. Biomedicines 2017
49
4

Antisense oligonucleotides in therapy for neurodegenerative disorders.
Melvin M Evers, Lodewijk J A Toonen, Willeke M C van Roon-Mom. Adv Drug Deliv Rev 2015
182
4

An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice.
Charles Preston Neff, Jiehua Zhou, Leila Remling, Jes Kuruvilla, Jane Zhang, Haitang Li, David D Smith, Piotr Swiderski, John J Rossi, Ramesh Akkina. Sci Transl Med 2011
195
4

Non-viral vectors for gene-based therapy.
Hao Yin, Rosemary L Kanasty, Ahmed A Eltoukhy, Arturo J Vegas, J Robert Dorkin, Daniel G Anderson. Nat Rev Genet 2014
4

Pharmacokinetics of antisense oligonucleotides.
S Agrawal, J Temsamani, W Galbraith, J Tang. Clin Pharmacokinet 1995
236
4

Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.
Ivan V Chernikov, Daniil V Gladkikh, Mariya I Meschaninova, Alya G Ven'yaminova, Marina A Zenkova, Valentin V Vlassov, Elena L Chernolovskaya. Mol Ther Nucleic Acids 2017
35
5

Oligonucleotide Therapies: The Past and the Present.
Karin E Lundin, Olof Gissberg, C I Edvard Smith. Hum Gene Ther 2015
160
4

Polymer-drug conjugate therapeutics: advances, insights and prospects.
Iriny Ekladious, Yolonda L Colson, Mark W Grinstaff. Nat Rev Drug Discov 2019
280
4

Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA.
Md Rowshon Alam, Xin Ming, Michael Fisher, Jeremy G Lackey, Kallanthottathil G Rajeev, Muthiah Manoharan, Rudy L Juliano. Bioconjug Chem 2011
78
4

Morpholino antisense oligomers: design, preparation, and properties.
J Summerton, D Weller. Antisense Nucleic Acid Drug Dev 1997
739
4

Nonviral vectors for gene delivery.
Meredith A Mintzer, Eric E Simanek. Chem Rev 2009
4

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.
Sarah C Darby, Sau Wan Kan, Rosemary J Spooner, Paul L F Giangrande, Frank G H Hill, Charles R M Hay, Christine A Lee, Christopher A Ludlam, Michael Williams. Blood 2007
355
4



Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B.
H Husseinzadeh, T Chiasakul, P A Gimotty, B Pukenas, R Wolf, M Kelty, E Chiang, P F Fogarty, A Cuker. Haemophilia 2018
10
20


Past, present and future of hemophilia: a narrative review.
Massimo Franchini, Pier Mannuccio Mannucci. Orphanet J Rare Dis 2012
133
4

Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
M J Manco-Johnson, B Lundin, S Funk, C Peterfy, D Raunig, M Werk, C L Kempton, M T Reding, S Goranov, L Gercheva,[...]. J Thromb Haemost 2017
68
4

Current and emerging factor VIII replacement products for hemophilia A.
Lorraine A Cafuir, Christine L Kempton. Ther Adv Hematol 2017
33
6


Haemophilia patients' unmet needs and their expectations of the new extended half-life factor concentrates.
S von Mackensen, W Kalnins, J Krucker, J Weiss, W Miesbach, M Albisetti, I Pabinger, J Oldenburg. Haemophilia 2017
37
5

Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study.
Annarita Tagliaferri, Giulio Feola, Angelo Claudio Molinari, Cristina Santoro, Gianna Franca Rivolta, Dorina Bianca Cultrera, Fabio Gagliano, Ezio Zanon, Maria Elisa Mancuso, Lelia Valdré,[...]. Thromb Haemost 2015
72
4

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.
David Adams, Ole B Suhr, Peter J Dyck, William J Litchy, Raina G Leahy, Jihong Chen, Jared Gollob, Teresa Coelho. BMC Neurol 2017
99
4

RNAi therapeutics: a potential new class of pharmaceutical drugs.
David Bumcrot, Muthiah Manoharan, Victor Koteliansky, Dinah W Y Sah. Nat Chem Biol 2006
736
4

Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.
Roberto Calcedo, Luk H Vandenberghe, Guangping Gao, Jianping Lin, James M Wilson. J Infect Dis 2009
470
4

Selection and evaluation of clinically relevant AAV variants in a xenograft liver model.
Leszek Lisowski, Allison P Dane, Kirk Chu, Yue Zhang, Sharon C Cunningham, Elizabeth M Wilson, Sean Nygaard, Markus Grompe, Ian E Alexander, Mark A Kay. Nature 2014
265
4

A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia - A success story from a resource limited country.
S P Verma, T K Dutta, S Mahadevan, P Nalini, D Basu, N Biswal, A Ramesh, D Charles, K V Vinod, K T Harichandra Kumar. Haemophilia 2016
52
4

Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.
Jonathan D Finn, Margareth C Ozelo, Denise E Sabatino, Helen W G Franck, Elizabeth P Merricks, Julie M Crudele, Shangzhen Zhou, Haig H Kazazian, David Lillicrap, Timothy C Nichols,[...]. Blood 2010
111
4

Advances in Gene Therapy for Hemophilia.
Amit C Nathwani, Andrew M Davidoff, Edward G D Tuddenham. Hum Gene Ther 2017
39
5

Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model.
Robert A French, Benjamin J Samelson-Jones, Glenn P Niemeyer, Clinton D Lothrop, Elizabeth P Merricks, Timothy C Nichols, Valder R Arruda. Blood Adv 2018
15
13



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.